3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neuroendocrine Tumors
2
Vipoma
1
Pheochromocytoma
1
Paraganglioma
1
Neoplasms, Unknown Primary
1
Insulinoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Gastrinoma
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Interventions
Gemcitabine
2
Taxes
1
Polymerase Chain Reaction
1
Paclitaxel
1
Magnetic Resonance Spectroscopy
1
Gene Expression Profiling
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Bevacizumab
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Neoplasms, Unknown Primary
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn